// App-Quantinova.ai

S243 : CMML PATIENTS UNDERGOING ALLOGENEIC HCT HAVE INFERIOR SURVIVAL OUTCOMES IN COMPARISON WITH MDS PATIENTS DUE TO A SIGNIFICANTLY HIGHER RELAPSE RATE. A REGISTRY STUDY OF THE EBMT-CMWP

Researchers

Presenter

  • Alicia Rov

Principal Investigators

  • Brian Piepenbroek

  • Nicolaus Krger

  • Hans Christian Reinhardt

  • Aleksandar Radujkovic

  • Didier Blaise

  • Guido Kobbe

  • Riitta Niittyvuopio

  • Uwe Platzbecker

  • Katja Sockel

  • Mathilde Hunault-Berger

  • J.J. Cornelissen

  • Edouard Forcade

  • Jean Henri Bourhis

  • Yves Chalandon

  • Charles Craddock

  • Stephanie Nguyen-Quoc

  • Johan Maertens

  • Ahmet Elmaagacli

  • Nicola Mordini

  • Patrick Hayden

  • Marie Robin

  • Francesco Onida

  • Ibrahim Yakoub-Agha

Medical Centers

  • CHU de Bordeaux, Pessac, France

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy

  • Programme de Transplantation &amp

  • Medical Clinic and Policlinic 1,Leipzig,Germany

  • Asklepios Klinik St. Georg, Hamburg, Germany

  • CHU, Angers, France

  • Sorbonne Universite, Hopital Pitie-Salpetriere, Paris, France

  • University Hospital Eppendorf Frauenklinik, Hamburg, Germany

  • Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Hematology,Rotterdam,Netherlands

  • University Clinic Heidelberg, Heidelberg, Germany

  • Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland

  • CHU de Lille, Univ Lille, INSERM U1286, Infinite,Lille,France

  • EBMT Leiden Study Unit,Leiden,Nederländerna

  • HUCH Comprehensive Cancer Center, Helsinki, Finland

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland

  • Department of Hematology and Stem Cell Transplantation,University of Duisburg-Essen,Essen,Germany

  • EBMT Statistical Unit,Leiden,Netherlands

  • Département d’Oncologie, Service d’Hématologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland

  • Medical Clinic and Policlinic I, University Hospital Dresden,TU Dresden,Dresden,Germany

  • Therapie Cellulaire,Marseille,France

  • Hospital Saint Antoine, Paris, France

Locations

  • France

  • Belgium

  • Italy

  • Germany

  • Netherlands

  • Switzerland

  • Finland

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved